News & Updates
Filter by Specialty:
Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity
Patients with heart failure (HF) with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes (T2D) show a favourable response to tirzepatide despite less pronounced weight loss, reports a study.
Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity
17 Sep 2025
Inactive disease a viable target in tofacitinib-treated patients with JIA
Treatment with tofacitinib improves the rates of Juvenile Arthritis Disease Activity Score (JADAS) in 10 joints (JADAS10)-clinically inactive disease (CID) and American College of Rheumatology (ACR)-CID in patients with juvenile idiopathic arthritis (JIA), with improvements sustained over time, a study has shown. Additionally, a few patients have achieved JADAS10 remission.
Inactive disease a viable target in tofacitinib-treated patients with JIA
16 Sep 2025
What’s hot at APS & MCV 2025?
MIMS Doctor brings you extensive coverage of the Asia Pneumonia Summit & MasterClass in Vaccinology 2025, held recently in Taipei, Taiwan. Check out the latest updates on RSV, pneumococcal disease, new vaccines, plus thought-provoking insights from respiratory experts. [READ THE FULL REPORT]
